A citation-based method for searching scientific literature

Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
Times Cited: 340



D J Gallagher, J A Konner, K M Bell-McGuinn, J Bhatia, P Sabbatini, C A Aghajanian, K Offit, R R Barakat, D R Spriggs, N D Kauff. Ann Oncol 2011
Times Cited: 70




List of shared articles



Times cited

BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Luis Felipe Sallum, Liliana Andrade, Larissa Bastos Eloy da Costa, Susana Ramalho, Amanda Canato Ferracini, Rodrigo de Andrade Natal, Angelo Borsarelli Carvalho Brito, Luis Otávio Sarian, Sophie Derchain. Int J Gynecol Cancer 2018
4



Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Iwona K Rzepecka, Lukasz M Szafron, Agnieszka Stys, Anna Felisiak-Golabek, Agnieszka Podgorska, Agnieszka Timorek, Piotr Sobiczewski, Barbara Pienkowska-Grela, Mona El-Bahrawy, Jolanta Kupryjanczyk. Gynecol Oncol 2017
5

Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.
Agnieszka Synowiec, Gabriel Wcisło, Lubomir Bodnar, Bohdan Górski, Jolanta Szenajch, Katarzyna Szarlej-Wcisło, Cezary Szczylik. Hered Cancer Clin Pract 2016
9

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer.
Wiktor Szatkowski, Paweł Blecharz, Jerzy W Mituś, Marek Jasiówka, Elżbieta Łuczyńska, Jerzy Jakubowicz, Tomasz Byrski. Hered Cancer Clin Pract 2016
0

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Renaud Sabatier, Elise Lavit, Jessica Moretta, Eric Lambaudie, Tetsuro Noguchi, François Eisinger, Elisabeth Cherau, Magali Provansal, Doriane Livon, Laetitia Rabayrol,[...]. Fam Cancer 2016
4

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.
Nicoletta Biglia, Paola Sgandurra, Valentina Elisabetta Bounous, Furio Maggiorotto, Eleonora Piva, Emanuele Pivetta, Riccardo Ponzone, Barbara Pasini. Ecancermedicalscience 2016
18

Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer.
Wiktor Szatkowski, Konrad Muzykiewicz, Marek Jasiówka, Kazimierz Karolewski, Zbigiew Kojs, Małgorzata Klimek, Paweł Blecharz. Ginekol Pol 2016
2

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Mariam M AlHilli, Marc A Becker, S John Weroha, Karen S Flatten, Rachel M Hurley, Maria I Harrell, Ann L Oberg, Matt J Maurer, Kieran M Hawthorne, Xiaonan Hou,[...]. Gynecol Oncol 2016
37

Treatment related toxicity in BRCA1-associated epithelial ovarian cancer - is DNA repairing impairment associated with more adverse events?
Agnieszka Badora-Rybicka, Magdalena Budryk, Elżbieta Nowara, Danuta Starzyczny-Słota. Contemp Oncol (Pozn) 2016
3